Explore the role of CR1 genetic variants in late-onset Alzheimer's disease susceptibility.
Journal
Psychiatric genetics
ISSN: 1473-5873
Titre abrégé: Psychiatr Genet
Pays: England
ID NLM: 9106748
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
5
8
2021
medline:
15
1
2022
entrez:
4
8
2021
Statut:
ppublish
Résumé
Complement component (3b/4b) receptor 1 (CR1) is an interesting candidate gene which has a close connection with Alzheimer's disease, and its polymorphisms have been reported to link to the late-onset Alzheimer's disease (LOAD) susceptibility. However, the findings of these related studies are inconsistent. Objective To explore the effect of CR1 genetic variants in LOAD susceptibility. MethodsWe searched relevant studies for the period up to 1 November 2020. And odds ratios (ORs) and their 95% confidence intervals (CIs) were utilized to assess the strength of the association. In addition, we carried out a case-control association study to assess their genetic association. Finally, a total of 30 articles with 30108 LOAD cases and 37895 controls were included. Significant allele frequency between LOAD patients and controls was observed in rs3818361 and rs6656401 (rs3818361, T vs. C: OR,1.18; 95% CI, 1.13-1.23; rs6656401, A vs. G: OR, 1.23; 95% CI, 1.10-1.36). Moreover, these results remain significant in subgroup of rs3818361 in Asia or America (OR,1.26; 95% CI,1.06-1.45; OR, 1.18; 95% CI, 1.13-1.24, respectively) and rs6656401 in Europe (OR = 1.26; 95% CI, 1.09-1.42). In addition, the two single nucleotide polymorphisms were proved to significantly increase LOAD risk in the overall population under the dominant model (OR = 1.12; 95% CI, 1.02-1.21; OR = 1.18, 95% CI, 1.15-1.22, respectively). Our case-control study showed that the distribution of rs6656401 genotype was significant (P = 0.000; OR, 6.889; 95% CI, 2.709-17.520), suggesting the A allele of rs6656401 is the risk allele. These available data indicate that rs6656401 in CR1 is significant to increase LOAD risk.
Sections du résumé
BACKGROUND
Complement component (3b/4b) receptor 1 (CR1) is an interesting candidate gene which has a close connection with Alzheimer's disease, and its polymorphisms have been reported to link to the late-onset Alzheimer's disease (LOAD) susceptibility. However, the findings of these related studies are inconsistent. Objective To explore the effect of CR1 genetic variants in LOAD susceptibility. MethodsWe searched relevant studies for the period up to 1 November 2020. And odds ratios (ORs) and their 95% confidence intervals (CIs) were utilized to assess the strength of the association. In addition, we carried out a case-control association study to assess their genetic association.
RESULTS
Finally, a total of 30 articles with 30108 LOAD cases and 37895 controls were included. Significant allele frequency between LOAD patients and controls was observed in rs3818361 and rs6656401 (rs3818361, T vs. C: OR,1.18; 95% CI, 1.13-1.23; rs6656401, A vs. G: OR, 1.23; 95% CI, 1.10-1.36). Moreover, these results remain significant in subgroup of rs3818361 in Asia or America (OR,1.26; 95% CI,1.06-1.45; OR, 1.18; 95% CI, 1.13-1.24, respectively) and rs6656401 in Europe (OR = 1.26; 95% CI, 1.09-1.42). In addition, the two single nucleotide polymorphisms were proved to significantly increase LOAD risk in the overall population under the dominant model (OR = 1.12; 95% CI, 1.02-1.21; OR = 1.18, 95% CI, 1.15-1.22, respectively). Our case-control study showed that the distribution of rs6656401 genotype was significant (P = 0.000; OR, 6.889; 95% CI, 2.709-17.520), suggesting the A allele of rs6656401 is the risk allele.
CONCLUSION
These available data indicate that rs6656401 in CR1 is significant to increase LOAD risk.
Identifiants
pubmed: 34347684
doi: 10.1097/YPG.0000000000000291
pii: 00041444-202112000-00002
doi:
Substances chimiques
CR1 protein, human
0
Receptors, Complement 3b
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
216-229Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. (2000). Inflammation and Alzheimer’s disease. Neurobiol Aging 21:383–421.
Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, et al.; Alzheimer’s Disease Genetics Consortium (ADGC) (2014). Genome-wide association meta-analysis of neuropathologic features of Alzheimer’s disease and related dementias. Plos Genet 10:e1004606.
Bellenguez C, Grenier-Boley B, Lambert JC (2020). Genetics of Alzheimer’s disease: where we are, and where we are going. Curr Opin Neurobiol 61:40–48.
Bonham LW, Desikan RS, Yokoyama JS; Alzheimer’s Disease Neuroimaging Initiative (2016). The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer’s disease. Acta Neuropathol Commun 4:65.
Camargo LM, Zhang XD, Loerch P, Caceres RM, Marine SD, Uva P, et al. (2015). Pathway-based analysis of genome-wide siRNA screens reveals the regulatory landscape of APP processing. PLoS One 10:e0115369.
Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, et al. (2010). Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol 67:961–964.
Chen LH, Kao PY, Fan YH, Ho DT, Chan CS, Yik PY, et al. (2011). Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer’s disease in a southern Chinese population. Neurobiol Aging 33:210.e1–210.e7.
Chibnik LB, Shulman JM, Leurgans SE, Schneider JA, Wilson RS, Tran D, et al. (2011). CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol 69:560–569.
Chung SJ, Lee JH, Kim SY, You S, Kim MJ, Lee JY, Koh J (2013). Association of GWAS top hits with late-ons et Al zheimer disease in Korean population. Alzheimer Dis Assoc Disord 27:250–257.
Crehan H, Hardy J, Pocock J (2013). Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis 54:139–149.
Davies C, Spires-Jones TL (2018). Complementing tau: new data show that the complement system is involved in degeneration in tauopathies. Neuron 100:1267–1269.
DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials 7:177–188.
Ferrari R, Moreno JH, Minhajuddin AT, O’Bryant SE, Reisch JS, Barber RC, Momeni P (2012). Implication of common and disease specific variants in CLU, CR1, and PICALM. Neurobiol Aging 33: 1846 e1847–1818.
Gandy S, Haroutunian V, DeKosky ST, Sano M, Schadt EE (2013). CR1 and the “vanishing amyloid” hypothesis of Alzheimer’s disease. Biol Psychiatry 73:393–395.
Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, et al. (2004). Systemic catabolism of Alzheimer’s Abeta40 and Abeta42. J Biol Chem 279:45897–45908.
Hamilton G, Evans KL, Macintyre DJ, Deary IJ, Dominiczak A, Smith BH, et al. (2011). Alzheimer’s disease risk factor complement receptor 1 is associated with depression. Neurosci Lett 510:6–9.
Hazrati LN, Van Cauwenberghe C, Brooks PL, Brouwers N, Ghani M, Sato C, et al. (2012). Genetic association of CR1 with Alzheimer’s disease: a tentative disease mechanism. Neurobiol Aging 33:2949.e5–2949.e12.
Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al.; Alzheimer’s Disease Neuroimaging Initiative; CHARGE consortium; EADI1 consortium (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43:429–435.
Hu J, Yang Y, Wang M, Yao Y, Chang Y, He Q, et al. (2019). Complement C3a receptor antagonist attenuates tau hyperphosphorylation via glycogen synthase kinase 3β signaling pathways. Eur J Pharmacol 850:135–140.
Huang F, Shang Y, Luo Y, Wu P, Huang X, Tan X, et al. (2016). Lower prevalence of Alzheimer’s disease among tibetans: association with religious and genetic factors. J Alzheimers Dis 50:659–667.
Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ (1994). beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol 152:5050–5059.
Jin C, Li W, Yuan J, Xu W, Cheng Z (2012). Association of the CR1 polymorphism with late-ons et Al zheimer’s disease in Chinese Han populations: a meta-analysis. Neurosci Lett 527:46–49.
Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, et al.; Alzheimer’s Disease Genetics Consortium (2010). Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 67:1473–1484.
Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM (2012). Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains. PLoS One 7:e50976.
Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, et al.; Alzheimer’s Disease Neuroimaging Initiative (2011). Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer’s disease. PLoS One 6:e15918.
Khera R, Das N (2009). Complement Receptor 1: disease associations and therapeutic implications. Mol Immunol 46:761–772.
Killick R, Hughes TR, Morgan BP, Lovestone S (2013). Deletion of Crry, the murine ortholog of the sporadic Alzheimer’s disease risk gene CR1, impacts tau phosphorylation and brain CFH. Neurosci Lett 533:96–99.
Klimkowicz-Mrowiec A, Sado M, Dziubek A, Dziedzic T, Pera J, Szczudlik A, Slowik A (2013). Lack of association of CR1, PICALM and CLU gene polymorphisms with Alzheimer disease in a Polish population. Neurol Neurochir Pol 47:157–160.
Kretzschmar GC, Antoniazzi AAH, Oliveira LC, Nisihara RM, Petzl-Erler ML, de Souza RLR, Boldt ABW (2020). First report of CR1 polymorphisms and soluble CR1 levels associated with late ons et Alzheimer’s disease (LOAD) in Latin America. J Mol Neurosci 70:1338–1344.
Kucukkilic E, Brookes K, Barber I, Guetta-Baranes T, Morgan K, Hollox EJ; ARUK Consortium (2018). Complement receptor 1 gene (CR1) intragenic duplication and risk of Alzheimer’s disease. Hum Genet 137:305–314.
Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. (2013). European Alzheimer’s Disease Initiative Investigators (2009). Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41:1094–1099.
Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. (2013). European Alzheimer’s Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer’s Disease; Alzheimer’s Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45:1452–1458.
Lewis CM, Knight J (2012). Introduction to genetic association studies. Cold Spring Harb Protoc 2012:297–306.
Li HL, Shi SS, Guo QH, Ni W, Dong Y, Liu Y, et al. (2014). PICALM and CR1 variants are not associated with sporadic Alzheimer’s disease in Chinese patients. J Alzheimers Dis 25:111–117.
Li Y, Song D, Jiang Y, Wang J, Feng R, Zhang L, et al. (2016). CR1 rs3818361 polymorphism contributes to Alzheimer’s disease susceptibility in Chinese population. Mol Neurobiol 53:4054–4059.
Logue MW, Schu M, Vardarajan BN, Buros J, Green RC, Go RC, et al.; Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (2011). A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol 68:1569–1579.
Luo J, Li S, Qin X, Song L, Peng Q, Chen S, et al. (2014). Meta-analysis of the association between CR1 polymorphisms and risk of late-onset Alzheimer’s disease. Neurosci Lett 578:165–170.
Ma XY, Yu JT, Tan MS, Sun FR, Miao D, Tan L (2013). Missense variants in CR1 are associated with increased risk of Alzheimer’ disease in Han Chinese. Neurobiol Aging 35:443.e17–443.e21.
Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748.
McGeer PL, Rogers J, McGeer EG (2016). Inflammation, antiinflammatory agents, and Alzheimer’s disease: the last 22 years. J Alzheimers Dis 54:853–857.
Miyashita A, Koike A, Jun G, Wang LS, Takahashi S, Matsubara E, et al.; Alzheimer Disease Genetics Consortium (2013). SORL1 is genetically associated with late-onset Alzheimer’s disease in Japanese, Koreans and Caucasians. PLoS One 8:e58618.
Moreno DJ, Ruiz S, Ríos Á, Lopera F, Ostos H, Via M, Bedoya G (2017). Association of GWAS top genes with late-onset Alzheimer’s disease in colombian population. Am J Alzheimers Dis Other Demen 32:27–35.
Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. (2011). Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43:436–441.
Ohara T, Ninomiya T, Hirakawa Y, Ashikawa K, Monji A, Kiyohara Y, et al. (2012). Association study of susceptibility genes for late-onset Alzheimer’s disease in the Japanese population. Psychiatr Genet 22:290–293.
Omoumi A, Fok A, Greenwood T, Sadovnick AD, Feldman HH, Hsiung GY (2014). Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population. Neurobiol Aging 35:936.e5–936.12.
Ortega-Rojas J, Morales L, Guerrero E, Arboleda-Bustos CE, Mejia A, Forero D, et al. (2016). Association analysis of polymorphisms in TOMM40, CR1, PVRL2, SORL1, PICALM, and 14q32.13 regions in Colombian Alzheimer disease patients. Alzheimer Dis Assoc Disord 30:305–309.
Poma AB, Guzman HV, Li MS, Theodorakis PE (2019). Mechanical and thermodynamic properties of Aβ42, Aβ40, and α-synuclein fibrils: a coarse-grained method to complement experimental studies. Beilstein J Nanotechnol 10:500–513.
Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, et al. (1992). Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 89:10016–10020.
Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, et al. (2006). Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging 27:1733–1739.
Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, et al. (2011). The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry 68:207–213.
Schott JM; ADNI Investigators (2012). Using CSF biomarkers to replicate genetic associations in Alzheimer’s disease. Neurobiol Aging 33:1486.e9–1486.15.
Shen N, Chen B, Jiang Y, Feng R, Liao M, Zhang L, et al. (2015). An updated analysis with 85,939 samples confirms the association between CR1 rs6656401 polymorphism and Alzheimer’s disease. Mol Neurobiol 51:1017–1023.
Shulman JM, Chen K, Keenan BT, Chibnik LB, Fleisher A, Thiyyagura P, et al. (2013). Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurol 70:1150–1157.
Teo YY, Fry AE, Clark TG, Tai ES, Seielstad M (2007). On the usage of HWE for identifying genotyping errors. Ann Hum Genet 71:701–703.
Thambisetty M, An Y, Nalls M, Sojkova J, Swaminathan S, Zhou Y, et al.; Baltimore Longitudinal Study of Aging and the Alzheimer’s Disease Neuroimaging Initiative (2013). Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry 73:422–428.
Toral-Rios D, Franco-Bocanegra D, Rosas-Carrasco O, Mena-Barranco F, Carvajal-García R, Meraz-Ríos MA, Campos-Peña V (2015). Evaluation of inflammation-related genes polymorphisms in Mexican with Alzheimer’s disease: a pilot study. Front Cell Neurosci 9:148.
Van Cauwenberghe C, Bettens K, Engelborghs S, Vandenbulcke M, Van Dongen J, Vermeulen S, et al. (2012). Complement receptor 1 coding variant p.Ser1610Thr in Alzheimer’s disease and related endophenotypes. Neurobiol Aging 34:2235.e1–2235.e6.
Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, et al. (2019). ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat Med 25:496–506.
Zhang P, Qin W, Wang D, Liu B, Zhang Y, Jiang T, Yu C (2015). Impacts of PICALM and CLU variants associated with Alzheimer’s disease on the functional connectivity of the hippocampus in healthy young adults. Brain Struct Funct 220:1463–1475.
Zhang Q, Yu JT, Zhu QX, Zhang W, Wu ZC, Miao D, Tan L (2010). Complement receptor 1 polymorphisms and risk of late-ons et Al zheimer’s disease. Brain Res 1348:216–221.
Zhu XC, Dai WZ, Ma T (2020). Impacts of CR1 genetic variants on cerebrospinal fluid and neuroimaging biomarkers in alzheimer’s disease. BMC Med Genet 21:181.
Zhu XC, Wang HF, Jiang T, Lu H, Tan MS, Tan CC, et al.; Alzheimer’s Disease Neuroimaging Initiative (2017). Effect of CR1 genetic variants on cerebrospinal fluid and neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts. Mol Neurobiol 54:551–562.
Zhu XC, Yu JT, Jiang T, Wang P, Cao L, Tan L (2015). CR1 in Alzheimer’s disease. Mol Neurobiol 51:753–765.